Table 4.
KEGG pathways enriched by 71 DEmRNAs involved in the Hub network.
| ID | Term description | Count | P-Value | Genes |
|---|---|---|---|---|
| mRNAs targeted by hsa-mir-93 | ||||
| hsa05206 | MicroRNAs in cancer | 4 | 0.000143218 | E2F1, KIF23, SOX4, E2F2 |
| hsa05161 | Hepatitis B | 3 | 0.000308336 | E2F1, E2F2, EGR2 |
| hsa04360 | Axon guidance | 3 | 0.000526831 | EPHA7, CFL2, DPYSL2 |
| hsa05219 | Bladder cancer | 2 | 0.000663363 | E2F1, E2F2 |
| hsa05223 | Nonsmall cell lung cancer | 2 | 0.001204323 | E2F1, E2F2 |
| hsa05166 | HTLV-I infection | 3 | 0.001580128 | E2F1, E2F2, EGR2 |
| hsa05214 | Glioma | 2 | 0.00160289 | E2F1, E2F2 |
| hsa05212 | Pancreatic cancer | 2 | 0.001650553 | E2F1, E2F2 |
| hsa05218 | Melanoma | 2 | 0.00189891 | E2F1, E2F2 |
| hsa05220 | Chronic myeloid leukemia | 2 | 0.002002919 | E2F1, E2F2 |
| hsa05222 | Small cell lung cancer | 2 | 0.002743232 | E2F1, E2F2 |
| hsa05215 | Prostate cancer | 2 | 0.002929728 | E2F1, E2F2 |
| hsa01522 | Endocrine resistance | 2 | 0.003455352 | E2F1, E2F2 |
| hsa04931 | Insulin resistance | 2 | 0.00431996 | PPP1R3B, SLC2A4 |
| hsa04110 | Cell cycle | 2 | 0.005526668 | E2F1, E2F2 |
| hsa04910 | Insulin signaling pathway | 2 | 0.006869918 | PPP1R3B, SLC2A4 |
| mRNAs targeted by hsa-mir-195 | ||||
| hsa04110 | Cell cycle | 4 | 0.00000555 | CHEK1, CCNE1, WEE1, CDC25A |
| hsa05200 | Pathways in cancer | 5 | 0.0000299 | CCNE1, RUNX1T1, FGF2, AKT3, WNT7A |
| hsa05205 | Proteoglycans in cancer | 4 | 0.0000382 | FGF2, AKT3, WNT7A, ITPR1 |
| hsa05166 | HTLV-I infection | 4 | 0.000093 | CHEK1, AKT3, WNT7A, MYB |
| hsa04914 | Progesterone-mediated oocyte maturation | 3 | 0.00010659 | CDC25A, AKT3, CPEB2 |
| hsa04922 | Glucagon signaling pathway | 3 | 0.000119603 | AKT3, ITPR1, SIK1 |
| hsa05206 | MicroRNAs in cancer | 4 | 0.000160144 | CCNE1, CDC25A, KIF23, RECK |
| hsa04114 | Oocyte meiosis | 3 | 0.000204986 | CCNE1, ITPR1, CPEB2 |
| hsa04151 | PI3K-Akt signaling pathway | 4 | 0.000265539 | CCNE1, FGF2, AKT3, MYB |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells | 3 | 0.00030972 | FGF2, AKT3, WNT7A |
| hsa05221 | Acute myeloid leukemia | 2 | 0.001317859 | RUNX1T1, AKT3 |
| hsa04115 | p53 signaling pathway | 2 | 0.001901017 | CHEK1, CCNE1 |
| hsa05218 | Melanoma | 2 | 0.00200813 | FGF2, AKT3 |
| hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2 | 0.002585615 | FGF2, AKT3 |
| hsa05222 | Small cell lung cancer | 2 | 0.002900294 | CCNE1, AKT3 |
| hsa05215 | Prostate cancer | 2 | 0.003097313 | CCNE1, AKT3 |
| hsa04750 | Inflammatory mediator regulation of TRP channels | 2 | 0.00372495 | ITPR1, ALOX12 |
| hsa04915 | Estrogen signaling pathway | 2 | 0.003798048 | AKT3, ITPR1 |
| hsa04725 | Cholinergic synapse | 2 | 0.004726968 | AKT3, ITPR1 |
| hsa04726 | Serotonergic synapse | 2 | 0.004808654 | ITPR1, ALOX12 |
| hsa04611 | Platelet activation | 2 | 0.005661192 | AKT3, ITPR1 |
| hsa04152 | AMPK signaling pathway | 2 | 0.005929498 | AKT3, FASN |
| hsa04728 | Dopaminergic synapse | 2 | 0.006389399 | AKT3, ITPR1 |
| hsa05162 | Measles | 2 | 0.0069621 | CCNE1, AKT3 |
| hsa04530 | Tight junction | 2 | 0.007256895 | AKT3, AMOTL1 |
| hsa04910 | Insulin signaling pathway | 2 | 0.007256895 | AKT3, FASN |
| hsa04210 | Apoptosis | 2 | 0.007356404 | AKT3, ITPR1 |
| hsa04310 | WNT signaling pathway | 2 | 0.007658643 | WNT7A, PRICKLE2 |
| hsa05161 | Hepatitis B | 2 | 0.00796643 | CCNE1, AKT3 |
| hsa04261 | Adrenergic signaling in cardiomyocytes | 2 | 0.008279735 | AKT3, TPM2 |
| hsa04150 | mTOR signaling pathway | 2 | 0.008814086 | AKT3, WNT7A |